AI-generated research brief — verify at source
Intensive Medical Treatment Shows No Reduction in MACE Among Women With ANOCA/INOCA
A randomised controlled trial enrolling 2,476 women with suspected angina and no obstructive coronary artery disease found that intensive medical treatment did not significantly reduce the composite of major adverse cardiovascular events compared with usual care over 2.5 years, with a hazard ratio slightly favouring usual care (HR 1.13, 95% CI 0.94–1.37, p=0.20). The result is inconclusive rather than definitively negative, as the trial was substantially underpowered due to lower-than-planned recruitment and meaningful contamination of the usual care arm.
What Was Studied
The WARRIOR trial investigated whether an intensive pharmacological regimen — combining a high-intensity statin, an ACE inhibitor or angiotensin receptor blocker, and aspirin — could reduce major ischaemic and cardiovascular events in women referred for coronary angiography who were found to have no obstructive coronary artery disease (ANOCA/INOCA). The primary composite outcome encompassed all-cause death, myocardial infarction, stroke or transient ischaemic attack, and hospitalisation for angina or heart failure.
How It Was Studied
This was a prospective, randomised, blinded-outcomes evaluation conducted across 71 sites in the United States. A total of 2,476 women with suspected ANOCA/INOCA were enrolled and randomly assigned to either intensive medical treatment (IMT) or usual care (UC). The mean participant age was 64 years, and the cohort was characterised by well-controlled blood pressure and low-density lipoprotein cholesterol at baseline, along with already-high rates of statin and ACEi/ARB use before enrolment. Participants were followed for a mean of 2.5 years, with outcomes adjudicated in a blinded fashion.
What Was Observed
- No significant difference in the primary MACE outcome: A total of 421 events occurred over 2.5 years — 221 in the IMT group and 200 in the usual care group. The point estimate slightly favoured usual care, indicating no meaningful benefit from intensive treatment (HR 1.13, 95% CI 0.94–1.37, p=0.20), and the confidence interval does not exclude a modest benefit or harm in either direction.
- Angina hospitalisation was the dominant driver of events: Among all components of the MACE composite, hospitalisations for angina contributed the most to the overall event count, underscoring the substantial symptom burden experienced by this population rather than hard ischaemic endpoints like myocardial infarction or death.
- Sensitivity analysis for contamination yielded an imprecise estimate: When the analysis was adjusted to account for contamination of the usual care group — reflecting baseline use of study medications — the estimated hazard ratio shifted toward a potential benefit (HR 0.74, 95% CI 0.352–1.558, p=0.43), but the confidence interval was very wide, making this estimate unreliable as a basis for conclusions.
- No significant differences were observed in secondary outcomes, including individual components of the MACE composite and quality of life measures, further supporting the overall neutral result of the trial.
Why This Matters
Women with ANOCA/INOCA represent a population with a high burden of chest pain, frequent hospitalisation, and poor quality of life, yet evidence-based treatment strategies for this group remain limited. The WARRIOR trial is among the largest dedicated randomised trials in this population and its neutral findings, combined with the predominance of angina-driven events, highlight that standard cardioprotective pharmacotherapy alone may be insufficient to address the underlying mechanisms driving symptoms and outcomes in these women. The authors explicitly call for further investigation, citing the unmet clinical need demonstrated by persistent event rates and resource utilisation.
How to Read This Result
Given the trial’s underpowered status due to lower-than-planned enrolment, the already-medicated baseline population, and substantial contamination of the usual care group, the neutral primary result should be interpreted as inconclusive rather than evidence that intensive medical treatment is ineffective in women with ANOCA/INOCA.
Limitations
Recruitment fell short of the planned target, leaving the trial underpowered to detect the expected treatment effect. The enrolled population was older than anticipated (mean age 64 years) with well-controlled cardiovascular risk factors at baseline, reducing the potential margin for improvement. Critically, a relatively high proportion of participants in the usual care group were already receiving statins and ACEi/ARB therapy before randomisation, which likely contaminated the comparator arm and diluted any detectable between-group difference. Together, these factors preclude any definitive conclusion about whether intensive medical treatment might or might not be helpful in this patient population.